Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
The Business Research Company’s Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON, UK, April 7, 2021 /EINPresswire.com/ Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
The companies operating in the biosimilars industry are continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships is shaping the rituximab biosimilars market. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd together announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche s Rituxan (rit
Pfizer halts biosimilar programs in crowded China market, sells plant to WuXi Biologics
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Reportable, Inc.: Health Canada Clears Pacylex Pharmaceuticals for New Phase 1 Clinical Trial to Evaluate PCLX-001 Capsules in the Treatment of Hematologic and Solid Tumor Cancers
Key Takeaways:
Scientists at the University of Alberta have recently published evidence that a new drug could work in blood cancers by targeting B-cell signaling.
Scientists at the University of Alberta also published a study showing potential in breast cancer.
PCLX-001 led to significant tumor regression in mouse models, including completely eliminating lymphoma tumors derived from a patient whose cancer had stopped responding to the standard therapies CHOP and Roche s Rituxan.
Click image above to view full announcement.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Rituximab Biosimilars Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global rituximab biosimilars market.
Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA and Intas Biopharmaceuticals Ltd.
The global rituximab biosimilars market is expected to decline from $1.84 billion in 2019 to $1.78 billion in 2020 at a compound annual growth rate (CAGR) of -3.22%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in
For-profit hospitals financial outlook is stable heading into 2021 despite COVID-19, Moody s says Patient volumes, adjusted admissions and federal funding contribute to the outlook, although outside factors could change this.
, Associate Editor
Despite the ongoing pandemic, the 2021 financial outlook for the global healthcare sector is mostly positive, as strong demand for products and services including those related to COVID-19 will more than offset lingering pressures from the public health emergency, according to Moody s Investors Service.
The demand will remain strong largely due to aging populations, improving access and the introduction of new and innovative products. The one caveat: Steadily rising healthcare expenditures, which will cause payers to continue to restrict utilization and lower prices.
vimarsana © 2020. All Rights Reserved.